SCHEMBL9909230

SCHEMBL9909230

COC(=O)c1ccc2ncc(Cl)c(-c3ccc(Cl)cc3OC)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HTR5A P47898 1/20 0.44
SCN9A Q15858 2/20 0.43
MAPK1 P28482 1/20 0.43
PIK3CA P42336 1/20 0.43
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
TP53 P04637 1/20 0.42
CYP2D6 P10635 1/20 0.42
ALOX15 P16050 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909170 0.90 TTR (0.47) HTR5ASCN9AMAPK1PIK3CAMAPK8
SCHEMBL9907559 0.88 HTR5A (0.44) MEN1KMT2AHTR5AMAPK1SMN1; SMN2
SCHEMBL9909169 0.86 PDE5A (0.45) MEN1KMT2AHTR5ASCN9AKDM4E
SCHEMBL9909240 0.84 HTR5A (0.64) HTR5A
SCHEMBL9909273 0.83 HTR5A (0.44) KMT2AHTR5ASCN9ANPC1RAB9A
SCHEMBL9907600 0.82 HTR5A (0.45) KMT2AHTR5ANPC1RAB9ASMN1; SMN2
SCHEMBL9907565 0.81 TP53 (0.47) HTR5ASMN1; SMN2TP53ALOX15KDM4E
SCHEMBL9907430 0.81 NR1H2 (0.43) SMN1; SMN2TP53ALOX15KDM4EMAPT
SCHEMBL9909289 0.81 MEN1 (0.45) MEN1KMT2AHTR5ASCN9ANPC1
SCHEMBL9909256 0.81 HTR5A (0.54) HTR5ATP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E MEN1 3631/4885KMT2A 1729/4885HTR5A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.